Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Indian Equities: A2Z, India Infoline, Koutons, Orient Green

India’s Bombay Stock Exchange’s Sensitive Index, or Sensex, fell 32.92, or 0.2 percent, to 19,982.88 at the 3:30 p.m. close in Mumbai. Shares of the following companies had unusual moves and stock symbols are in parentheses.

A2Z Maintenance & Engineering Services Ltd. (A2ZL IN) lost 18 percent to 328.55 rupees as shares in the engineering firm backed by billionaire Rakesh Jhunjhunwala commenced trading.

India Infoline Ltd. (IIFL IN) advanced 1.1 percent to 83.25 rupees. About 1.4 percent of its shares changed hands in a single transaction on the Bombay Stock Exchange, according to Bloomberg data. Buyers and sellers weren’t immediately known.

Koutons Retail India Ltd. (KUTN IN) climbed 1.6 percent to 58.5 rupees, its highest in three weeks after eight days of gains. The menswear retailer and manufacturer is considering as much as a 15 percent stake sale to raise money to reduce its debt, the Economic Times reported, citing an unidentified person familiar with the development. Managing Director Bhupinder Singh Sawhney couldn’t immediately be reached at his office telephone for comment.

Orient Green Power Co. (OGPL IN) gained 3.4 percent to 30.3 rupees, its highest since Dec. 3. Goldman Sachs Investments Mauritius I Ltd. sold 8.42 million shares of the developer of renewable energy projects, according to data on the Bombay Stock Exchange and the National Stock Exchange.

Sun Pharmaceutical Industries Ltd. (SUNP IN), India’s largest drugmaker by market value, rose 5 percent to 452.95 rupees, the most in a year. The U.S. Court of Appeals for the Federal Circuit ruled in its favor in a case involving the cancer drug Eloxatin.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.